BRUIN CLL-313: Randomized Phase III Trial of Pirtobrutinib Versus Bendamustine Plus Rituximab in Untreated Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Authors:
- Wojciech JurczakWJWojciech Jurczak
- Jaroslaw CzyzJCJaroslaw Czyz
- Ki-Seong EomKEKi-Seong Eom
- Alexander EgleAEAlexander Egle
- Anna PanovskaAPAnna Panovska
- Zhanet Grudeva PopovaZPZhanet Grudeva Popova
- Hsuan-Jen ShihHSHsuan-Jen Shih
- Luis Felipe Casado MonteroLMLuis Felipe Casado Montero
- Paolo SportolettiPSPaolo Sportoletti
Top Cited Papers
Open Access
- 20 February 2026
- journal article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 44 (6) , 466-475
Abstract
PURPOSE: BRUIN CLL-313 is a randomized, open-label, global phase III study comparing the efficacy and safety of pirtobrutinib, a highly selective, noncovalent Bruton tyrosine kinase inhibitor (BTKi), against bendamustine plus rituximab (BendaR), a common frontline chemoimmunotherapy, in treatment-naïve patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). METHODS: Patients with previously untreated CLL/SLL without del(17p) were randomly assigned 1:1 to continuous pirtobrutinib monotherapy or BendaR, stratified by immunoglobulin heavy chain gene mutation status and Rai stage. The primary end point was independent review committee (IRC)–assessed progression-free survival (PFS); secondary end points included overall survival (OS), investigator (INV)–assessed PFS, safety, and tolerability. RESULTS: Overall, 282 patients were randomly assigned to receive pirtobrutinib (n = 141) or BendaR (n = 141). IRC-assessed PFS was significantly improved with pirtobrutinib versus BendaR (hazard ratio [HR], 0.199 [95% CI, 0.107 to 0.367]; P < .0001), and the 24-month PFS rate was 93.4% (95% CI, 87.6 to 96.5) and 70.7% (95% CI, 61.5 to 78.1), respectively. INV-assessed PFS similarly favored pirtobrutinib (HR, 0.186 [95% CI, 0.093 to 0.371]). Interim analysis of OS favored pirtobrutinib (median follow-up 32 months; HR, 0.257 [95% CI, 0.070 to 0.934]) despite an effective crossover rate of 52.9%. In patients receiving pirtobrutinib versus BendaR: adverse event (AE)–related dose reductions occurred in 3.6% versus 31.1% of patients; grade ≥3 treatment-emergent AEs (TEAEs) occurred in 40.0% versus 67.4% of patients; and treatment discontinuations because of TEAEs occurred in 4.3% versus 15.2% of patients, respectively. CONCLUSION: Pirtobrutinib demonstrated superiority over BendaR in IRC-assessed PFS in treatment-naïve CLL/SLL. OS trends favored pirtobrutinib despite the study design allowing for crossover. Pirtobrutinib was well tolerated, consistent with its known safety profile, and more favorable than BendaR.Keywords
This publication has 17 references indexed in Scilit:
- CLL-984: CLL18/MOIRAI International Phase 3 Trial: Aiming to Establish Measurement of Individual Residual Disease for Adjustment of Treatment Duration to Improve Outcomes in First-Line Treatment of CLL/SLLClinical Lymphoma Myeloma and Leukemia, 2025
- P648: REAL-WORLD TREATMENT AND OUTCOMES OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) RECEIVING FIRST-LINE (1L) THERAPY IN THE NOVEL AGENT ERA: AN INTERNATIONAL STUDYHemaSphere, 2023
- Pirtobrutinib after a Covalent BTK Inhibitor in Chronic Lymphocytic LeukemiaNew England Journal of Medicine, 2023
- Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase 3 trialThe Lancet Oncology, 2022
- Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 studyThe Lancet, 2021
- Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open-label, randomised, phase 3 trialThe Lancet Oncology, 2020
- Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzumab for treatment-naive chronic lymphocytic leukaemia (ELEVATE-TN): a randomised, controlled, phase 3 trialThe Lancet, 2020
- Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 studyLeukemia, 2019
- Ibrutinib–Rituximab or Chemoimmunotherapy for Chronic Lymphocytic LeukemiaNew England Journal of Medicine, 2019
- Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLLNew England Journal of Medicine, 2018